Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
73 hedge funds and large institutions have $905M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 6 closing their positions.
256% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 9
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
18% more funds holding
Funds holding: 62 → 73 (+11)
2% more capital invested
Capital invested by funds: $891M → $905M (+$14.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$17M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.6M |
| 3 |
BlackRock
New York
|
+$13.1M |
| 4 |
Morgan Stanley
New York
|
+$6.88M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$26.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.4M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$10.4M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$4.47M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.19M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
76
HRT Financial
New York
| – | -$470K | -20,213 | Closed |
|
77
Squarepoint
New York
| – | -$309K | -13,272 | Closed |
|
78
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$239 | +11 | New |
|
KNTE Hedge Fund Activity: Q3 2021 in Review
73 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2021, worth a combined $905M — up 1.6% from $891M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KNTE positions and 6 closed out — a net gain of 11 holders — while 32 added to existing stakes and 9 trimmed.
The largest buyer was Boxer Capital, adding an estimated $17M. The largest seller was Logos Global Management, cutting an estimated $26.9M.
- 73 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2021, up from 62 in Q2 2021.
- Funds reported $905M of Kinnate Biopharma Inc. Common Stock stock for Q3 2021, up 1.6% quarter-over-quarter.
- 17 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of +11 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2021 was Boxer Capital, an estimated $17M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2021 was Logos Global Management, an estimated $26.9M sold.
Based on aggregated 13F filings for Q3 2021.